| Flat View | Saturday, April 04, 2026 |
|
| Saturday, December 01, 2012 |
 |
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
| Sunday, December 30, 2012 |
|
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
|
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
